Abbvie Inc ABBV

$265.76 +2.94 (1.12%)

Valuation

Market cap
464,348,544,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
23.91
Forward PE
18.51
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
7,544,500
Avg volume
4,714,464
Day's range
$260.29 – $267.34
Shares out
1,766,793,000
Stochastic %K
68%
Beta
0.24
Analysts
Strong Sell
Price target
$278.20

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

seven01trades Oct 6, 2:46 AM
$ABBV FRESH AFTER-HOURS SEC FILING: AbbVie updated its 2026 adjusted EPS guidance to $13.76–$13.96, versus the previously announced $13.87–$14.07 range. The change reflects approximately $216M of Q3 acquired IPR&D and milestone expense, which reduces adjusted EPS by about $0.11/share. Q3 adjusted EPS guidance is now $3.73–$3.77 versus $3.84–$3.88 previously. Important context: this is primarily an accounting impact from acquired R&D/milestone expense—not a newly disclosed deterioration in the underlying business. The 8-K was accepted by the SEC at 4:07 PM ET today, Oct. 5.
1 replies
nlrmandate Oct 5, 9:07 PM
$VKTX I'm really hoping that after all that happened with the offering, retail reaction to it, whatever happened with Neil, etc., that someone (perhaps Morgan Stanley or Goldman) will serve as matchmaker between $NVO or $ABBV and the Viking BOD/management. Hopefully BL will realize soon that perhaps 15-17.5B is enough for a full BO of a company with an asset that can compete with Terz and Reta or 8-12B for a 50% partnership of said asset. 🙏🙏🙏. Still long and insanely
1 replies
topstockalerts Oct 5, 8:11 PM
Genmab reported positive preliminary Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The EPCORE DLBCL-2 trial, conducted with AbbVie, showed a statistically significant improvement in progression-free survival among patients with International Prognostic Index scores of 2–5, reducing the risk of disease progression or death by 51% (hazard ratio 0.49). The company said this is the first Phase 3 study of a bispecific-antibody combination to demonstrate such an improvement in first-line DLBCL. Epcoritamab is a subcutaneous T-cell-engaging bispecific antibody already approved in several lymphoma indications across more than 65 countries under the EPKINLY and TEPKINLY brands. Genmab and AbbVie plan to engage global regulators on next steps and present the data at a future medical meeting. The epcoritamab/R-CHOP combination remains investigational and is not yet approved. $GMAB $ABBV
0 replies
easydollars1 Oct 5, 8:09 PM
$ABBV $GMAB when 100% run on this $SPY
0 replies
notreload_ai Oct 5, 8:00 PM
$GMAB and $ABBV say epcoritamab plus R-CHOP cut the risk of progression or death by 51% in newly diagnosed DLBCL in a Phase 3 trial. https://notreload.xyz/xy/genmab-abbvie-dlbcl-combo-cuts-progression-risk-by-51/
0 replies
SenefAS Oct 5, 7:49 PM
I hope you are on the train of Genmab 😉 … $GMAB $ABBV Next one on the radar it’s Ascendis $ASND
0 replies
focafoca99 Oct 5, 7:05 PM
$ABBV describes positive Phase 3 EPCORE DLBCL-2 results showing epcoritamab plus R-CHOP cut risk of progression by 51% in frontline DLBCL. https://www.rapidticker.com/news/abbv-abbvie-and-genmab-announce-epcoritamab-8562cb
0 replies
flychicken1991 Oct 5, 6:54 PM
$ABBV Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Impact: Positive (87%). faces upward valuation pressure because successful frontline expansion could increase expected epcoritamab revenue and future cash flow attributable to AbbVie's commercial participation. Source and what to watch next: https://nimpact.tech/newsimpact/news/61b4015f0450490e/abbv-genmab-and-abbvie-announce-epcoritamab-in-combination-with-r-chop-d?utm_source=stocktwits&utm_medium=story_url
0 replies